Why ICON Public Limited Company’s (ICLR) Stock Is Down 8.52%
As of Thursday, July 30, ICON Public Limited Company’s ICLR share price has dipped by 8.52%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: ICON Public Limited Company (ICLR)
ICON Public Limited Company ICLR
$163.57
-1.97
-1.19%
July 31, 2026 4:00:00 PM
EST
Volume: 871,853
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Commentary & Analysis
Why ICON Public Limited Company’s (ICLR) Stock Is Up 8.32%
As of Tuesday, July 28, ICON Public Limited Company’s ICLR share price has surged by 8.32%, which has investors questioning if this is right time to sell.Michael Rose
Why ICON Public Limited Company’s (ICLR) Stock Is Up 5.26%
As of Thursday, July 23, ICON Public Limited Company’s ICLR share price has surged by 5.26%, which has investors questioning if this is right time to sell.Michael Rose
Is ICON Public Limited Company (ICLR) Overvalued?
We dive into why ICON Public Limited Company (ICLR) could be considered overvalued on 2026-07-22, based on AAII’s Value Score and Grade.Tudor Pop
Why ICON Public Limited Company’s (ICLR) Stock Is Up 5.10%
As of Friday, June 26, ICON Public Limited Company’s ICLR share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ICLR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12,771.3 | $1,774.7 | 81% |
|
| Shares Out (Mil) | 77.3 | 94.8 | 57% |
|
| Institutional Ownership | 99.6% | 90.1% | 91% |
|
| Float (Mil) | 76.3 | 69.9 | 56% |
|
| Beta | 1.22 | 1.20 | 71% |
|
| Avg Daily Volume (000s) | 1,038 | 838 | 71% |
|
| Price Change (52-week) |
(10.6%) | 81.0% | 37% |
|
| Growth | ICLR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.2% | 7.8% | 85% |
|
| Net Income (5yr) | (8.4%) | (13.7%) | 30% |
|
| EPS (5yr) | (15.1%) | 0.7% | 18 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (25.6%) | (15.0%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 15 | 17 | 16 | |
| Current EPS | $2.517 | $10.640 | $11.860 | |
| Month Ago EPS | $2.540 | $10.618 | $11.816 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.911 | $11.824 | $12.782 | |
| Year/Year Chg | 85.1% | 292.6% | 391.3% | |
| Financials | ICLR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8,270 | $763 | 82% |
|
| Net Income (TTM) (Mil) | $173 | ($14) | 67% |
|
| EPS (TTM) | $2.238 | ($0.200) | 73% |
|
| Operating Cash Flow (TTM) (Mil) | $935 | $53 | 80% |
|
| Net Cash Flow (TTM) (Mil) | $239 | ($5) | 86% |
|
| Long-Term Debt (Q1) (Mil) | $2,978 | $270 | 80% |
|
| Enterprise Value (Q1) (Mil) | $16,187 | $2,430 | 81% |
|
| Valuation | ICLR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.36 | 3.00 | 35% |
|
| P/E | 74.7 | 43.5 | 90% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | ICLR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 25.3% | 47.6% | 28% |
|
| Net Margin | 2.1% | (2.9%) | 38% |
|
| ROA | 1.0% | (3.2%) | 46% |
|
| ROE | 1.8% | (4.5%) | 38% |
|
| Liabilities to Assets | 43.0% | 43.0% | 34% |
|
| F-Score | 6 | 5 | 69% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
